On September 5, 2024, HDAX Therapeutics (“HDAX”), a biotech company innovating in HDAC6-targeted therapies for neurological and cardiometabolic diseases, announced the successful first closing of an oversubscribed US$3.2 million seed financing round.
The round was led by SeedFolio, FACIT, and Toronto Innovation Acceleration Partners, with additional contributions from Eos Bioinnovation, the Ontario Centre of Innovation, and other investors.
HDAX is at the forefront of developing next-generation HDAC6-targeting therapeutics to enhance patient outcomes. Its novel binding mechanism effectively and safely targets disease drivers, positioning it as potentially best-in-class. The funds from this seed financing will support the nomination of a preclinical development candidate and advance pipeline programs.
Fasken advised HDAX with a team comprised of Will Shaw, Chris Dittrich and Veronique Poulin.
Jurisdiction
- Ontario
